Physiological Reports

Open Access

Physiological Reports ISSN 2051-817X

ORIGINAL RESEARCH

Leukotriene D₄-induced Caco-2 cell proliferation is mediated by prostaglandin E₂ synthesis

Marisol Cabral, Raquel Martín-Venegas & Juan J. Moreno

Departament de Fisiologia, Facultat de Farmàcia, Universitat de Barcelona, Barcelona, Spain

Keywords

5-lipoxygenase, arachidonic acid cascade, cell cycle, cell growth, colon cancer.

Correspondence

Juan José Moreno, Departament de Fisiologia, Facultat de Farmàcia, Universitat de Barcelona, Avda. Joan XXIII s/n, 08028 Barcelona, Spain.

Tel: +34 93 402 4505 Fax: +34 93 403 5901 E-mail: jjmoreno@ub.edu

Funding Information

This research was supported by Spanish Ministry of Science and Innovation (BFU2007-61727/BFI) and by the *Generalitat* (Autonomous Government) of Catalonia (2009SGR0438). Universitat de Barcelona has supported open access publication charge.

Received: 11 March 2015; Revised: 5 May 2015; Accepted: 6 May 2015

doi: 10.14814/phy2.12417

Physiol Rep, 3 (7), 2015, e12417, doi: 10.14814/phy2.12417

Abstract

Leukotriene D₄ (LTD₄) is a pro-inflammatory mediator formed from arachidonic acid through the action of 5-lipoxygenase (5-LOX). Its biological effects are mediated by at least two G-coupled plasmatic cysteinyl LT receptors (Cys-LT₁₋₂R). It has been reported an upregulation of the 5-LOX pathway in tumor tissue unlike in normal colon mucosa. Colon tumors generally have an increased expression of CysLT₁R and colon cancer patients with high expression levels of CysLT₁R have poor prognosis. We previously observed that the cyclooxygenase pathway is involved in the control of intestinal epithelial cancer cell growth through PGE₂ production. The aim of this study was therefore to assess the effect of LTD4 binding with CysLT1R on Caco-2 cell growth. We note a number of key findings from this research. We observed that at a concentration similar to that found under inflammatory conditions, LTD4 was able to induce Caco-2 cell proliferation and DNA synthesis. Moreover, with the use of a specific receptor antagonist this study has demonstrated that the effect of LTD₄ is a result of its interaction with CystLT₁R. We also note the possible participation of the PLC-IP3-Ca2+/DAG-PKC signaling pathways in cytosolic PLA₂ and [³H]AA release induced by LTD₄-CystLT₁R interaction. Finally, we found that the resulting activation of the AA cascade and the production of PGE₂ eicosanoid could be related to the activation of cell signaling pathways such as ERK and CREB. These findings will help facilitate our understanding of how inflammatory mediators can affect the survival and dissemination of intestinal carcinoma cells.

Introduction

Leukotriene D₄ (LTD₄) is a powerful pro-inflammatory mediator, which is formed from arachidonic acid through the action of 5-lipoxygenase (5-LOX) (Samuelsson 1979). LTD₄ mediates its effects through specific cell surface receptors that belong to the G protein-coupled receptor family, cysteinyl leukotriene receptors (CysLTR). Two such receptors have previously been cloned: CysLT₁R (Lynch et al. 1999) and CysLT₂R (Heise et al. 2000). CysLT₁R has the highest affinity of the two receptors (Heise et al. 2000). As such it has a higher affinity for LTD₄ than CysLT₂R (Lynch et al. 1999).

LTD₄ is associated with the pathogenesis of several inflammatory disorders such as inflammatory bowel disease (IBD) (Stenton 1990). Not only is there a well-established connection between IBD and increased frequency of neoplastic transformation (Smalley and Dubois 1997), but a more general link between chronic inflammation and an increased risk of developing cancer has been suggested in previous studies (Coussens and Werb 2002). A cause-and-effect link has been established between chronic inflammation and colon cancer, which occurs via the activation and over-expression of the enzymes 5-LOX and cyclooxygenase-2 (COX-2). These enzymes are responsible for regulating the production of

LTs and prostaglandins (PGs), respectively (Coussens and Werb 2002; Qiao and Li 2014). Unlike non-transformed human epithelial cells, CysLT₂R is downregulated in the colon cancer cell lines (Magnusson et al. 2007). In contrast, it has been demonstrated that CysLT₁R is upregulated in colon cancer tissue and that the binding of LTD₄ to this receptor facilitates the survival of the cells in this tissue and negatively correlates with patient survival (Öhd et al. 2000, 2003). In accordance with this trend, Magnusson et al. (2007, 2010) recently observed that colon cancer patients with high expression levels of CysLT₁R exhibited a poor prognosis. Moreover, as noted by Yudina et al. (2008), LTD₄ upregulates 5-LOX, COX-2, and CysLT₁R levels in intestinal epithelial cells providing a mechanism for maintaining inflammation and tumor progression.

In our study, we observed that through $CysLT_1R$ binding, LTD_4 increases the release of arachidonic acid (AA) and the synthesis of PGE_2 . In addition, we found that this prostaglandin is responsible for the proliferative effects induced by LTD_4 on intestinal epithelial Caco-2 cells.

Materials and Methods

Materials

LTD₄, PGE₂ and murine COX-2 were purchased from Cayman Chemical (Ann Arbor, MI). Non-essential amino acids, FBS, BSA, Fura-2 acetoxymethylester (Fura-2 AM), U73122, dantrolene, Gö 6983, ketoprofen, LY 171883, MK 571, NS 398, SC560 and SC19220, PD98059, ethidium bromide and acridine orange were purchased from Sigma Chemical (St. Louis, MO). LY 255283 was purchased from Tocris Biosc. (Bristol, UK). Arachidonyl trifluoromethylketone (AACOCF₃) and bromoenol lactone (BEL) were acquired from Alexis Corp. (San Diego, CA). [Methyl-³H]thymidine (20 Ci/mmol) and [5,6,8,9,11,12,-14,15-³H] arachidonic acid ([³H]AA) (60-100 Ci/mmol) were from American Radiolabeled Chemicals Inc. (St. Louis, MO), and AH 23838 was kindly provided by Glaxo-Wellcome (Stevenage, UK).

Cell culture and cell growth assay

Caco-2 cells, derived from a colon adenocarcinoma, were provided by the American Type Culture Collection (HTB-37, Manassas, VA). The cells were routinely grown in plastic flasks at a density of 10⁴ cells/cm² and cultured in DMEM supplemented with 4.5 g/L D-glucose, 1% (v/ v) nonessential amino acids, 2 mmol/L L-glutamine, 10% (v/v) heat-inactivated FBS, 100 U/mL penicillin and 0.1 mg/mL streptomycin at 37°C in a modified atmosphere of 5% CO₂ in air, as previously described (Martín-

Venegas et al. 2006). The growth medium was replaced twice per week and the day before the experiment. All the experiments were performed in pre-confluent cultures and consequently, in nondifferentiated cells. Caco-2 cell differentiation began when they reached the confluence and finished after 2 weeks postconfluence, following a previously described process (Martín-Venegas et al. 2006).

To perform the cell growth assay, cells were harvested with trypsin/EDTA and passed to 12 mm plastic clusters at a density of 10^4 cells/cm². After 4 days in culture, cells were incubated with treatments for a period of 48 h. Then, cell density was around 40 and 80×10^3 cells/cm² in absence or presence of FBS, respectively. Consequently all experiments were performed before reaching cell confluence. Cells were then washed, trypsinized, and counted with a microscope using ethidium bromide/acridine orange staining to view the number of viable cells (Parks et al. 1979).

Analysis of DNA synthesis

DNA synthesis was measured using a [3H]thymidine incorporation assay. Caco-2 cell cultures were kept on 24-well plates in DMEM with 10% FBS at a density of 10^4 cells/cm 2 . After 4 days in culture, the cells were incubated for 48 h with the treatments; [3H]thymidine (0.1 μ Ci/well) was added for the last 24 h. The media containing [3H]thymidine were then aspirated and cells were washed, overlaid with 1% Triton X-100 and scraped off the wells (Cabral et al. 2013). Finally, radioactivity present in the cell fraction was measured by scintillation counting, using a Packard Tri-Carb 1500 counter (Downers Grove, IL).

Prostaglandin E₂ (PGE₂) analysis by enzyme immunoassay

PGE₂ determination was performed using a competitive EIA kit (Cayman, Ann Arbor, MI) following the manufacturer's instructions. Briefly, following a previously described process cells were maintained in 12 mm plastic clusters at a density of 10⁴ cells/well (Cabral et al. 2013). After 4 days in culture, Caco-2 cells were incubated for 60 min at 37°C with LTD₄ (10 nmol/L) in the absence or presence of Cys-LT₁R antagonists or a COX inhibitor. Finally supernatants were harvested and PGE₂ was determined.

Incorporation and release of [3H]AA

Cells were harvested with trypsin/EDTA and passed to 24-well plates at a density of 10⁴ cells/cm². After 4 days, cells were FBS starvated during 24 h and then the medium was replaced by 0.5 mL DMEM containing 0.1% fatty acid free

BSA and 0.1 µCi [3H]AA (1 nmol/L) for a period of 6 h. Cells were then washed three times with 0.5% BSA-containing medium to remove any unincorporated [3H]AA. After the study period (2 h), the medium was removed to determine the amount of [3H] radioactivity release. The amount of [3H]AA released into the medium was expressed as a percentage of cell-incorporated [3H]AA, which was determined in solubilized cells, as previously described (Martín-Venegas et al. 2006).

Western blot analysis

Cells were seeded in 60 mm plastic clusters (10⁴ cells/ cm²) and after 4 days the cultures were washed twice with ice-cold PBS, scraped off into PBS containing 2 mmol/L sodium EDTA and pelleted. These pellets were sonicated in PBS containing 4 mmol/L sodium EDTA, 500 µg/mL aprotinin, 500 µg/mL leupeptin, 500 µg/mL PMSF, and 400 μg/mL diethyldithiocarbamic acid, then resuspended in a lysis buffer containing 200 mmol/L Tris-HCl, 200 mmol/L NaCl, 2% Igepal CA-630 and 200 μmol/L DTT. Finally, an immunoblot analysis for COX-2 was performed, as previously described (Martín-Venegas et al. 2006). For β -actin immunoblotting, the monoclonal actin antibody (1:500) was used (Santa Cruz, Dallas, TX).

Measurement of the cell signaling activated by eicosanoids

Cells were seeded in 60 mm plastic clusters (10⁴ cells/cm²) and after 4 days the cultures were incubated with the treatments (5 or 15 min) as previously described (Cabral et al. 2013). To measure the kinase activity with total cell lysates, Caco-2 cells were lysed using a denaturing cell lysis buffer containing 6 mol/L urea and protease (leupeptin 2 µg/mL, pepstatin 10 μmol/L, aprotinin 3 μg/mL) and phosphatase (NaF 5 mmol/L, Na₄P₂O₇ 2 mmol/L, Na₃VO₄ 1 mmol/L) inhibitors. The resulting solutions containing 80-100 µg of proteins were then added to kinase ELISA plate and the assay was performed, following the manufacturer's instructions (Symansis, Auckland, New Zealand). Optical density was then measured at 450 nm using a TECAN absorbance reader (Tecan Austria Gmbh, Salzburg, Austria). This simultaneous assay for the activation of multiple kinases provides a qualitatively better alternative to western blotting. We studied the effect of eicosanoids on the phosphorylation of Akt1 (pS473), Akt2 (pS474), ERK1/2 (pT202/ Y204; pT185/Y187), GSK3β (pS9), p38α (pT180/Y182) and CREB (pS133) on the dephosphorylation of β-catenin (DP S33/S37/S41). The phosphorylation of Akt, ERK and p38 was measured after 5 min incubation with LTD4, whereas the phosphorylation of CREB, GSK and the dephosphorylation of β-catenin was assayed after 15 min.

Statistical analysis

Results are expressed as mean \pm SEM. All data were compared by one-way ANOVA and Student's t-test using SPSS software (SPSS Inc., Chicago, IL). P < 0.05 was considered to denote significance.

Results

Figure 1 shows that LTD₄ (1-100 nmol/L) increases the number of viable cells in Caco-2 cell cultures in comparison with the results obtained in the absence of any growth factor. We note that the effect induced by LTD₄ (10 nmol/L) was reduced in the presence of CysLT₁R antagonists (MK 571 and LY 171883), a COX inhibitor (ketoprofen), a specific COX-2 inhibitor (NS 398), and EP₁ or EP₄ antagonists (SC 19220 and AH 23848, respectively) (Fig. 1), whereas the effect of specific COX-1 inhibitor (SC 560) did not reach significance. The mentioned treatments did not cause cell detachment nor a decrease in cell viability at the concentrations tested, as confirmed by microscopic observation (data not shown).




Figure. 1. The effect of Leukotriene D₄ (LTD₄) on Caco-2 cell growth. Cells were incubated for 48 h in the presence of LD₄ (1-100 nmol/L) and in the absence of growth factors (FBS); cells were then counted. Cell growth in control conditions (in the absence or presence of FBS) was included. LTD₄ (10 nmol/L) was incubated in the presence of MK 571 (MK5, 25 µmol/L), LY171883 (LY1, 25 μmol/L), ketoprofen (Kp, 5 μmol/L), SC 560 (SC5, 60 nmol/L), NS 398 (NS, 5 μmol/L), SC 19220 (SC1, 60 nmol/L) or AH 23838 (AH, 20 nmol/L). Results are expressed as mean \pm SEM of 4-5 determinations performed in triplicate. *P < 0.05 versus Caco-2 cells cultured without FBS; ${}^{\varphi}P$ < 0.05 versus Caco-2 cells cultured with FBS; #P < 0.05 versus Caco-2 cells cultured with LTD₄ (10 nmol/L)




Figure 2. The effect of Leukotriene D₄ (LTD₄) on DNA synthesis. Caco-2 cells were incubated for 48 h in the presence of LTD₄ (10 nmol/L) and in the absence of growth factors (FBS); [³H] thymidine incorporation into cells was then measured. DNA synthesis in control conditions (in the absence or presence of FBS) was included. LTD₄ (10 nmol/L) was incubated in the presence of MK 571 (MK5, 25 μmol/L), LY171883 (LY1, 25 μmol/L), ketoprofen (Kp, 5 μmol/L), SC 560 (SC5, 60 nmol/L), NS 398 (NS, 5 μmol/L), SC 19220 (SC1, 60 nmol/L) or AH 23838 (AH, 20 nmol/L). Results are expressed as mean \pm SEM of 4–5 determinations performed in triplicate. *P < 0.05 versus Caco-2 cells cultured with FBS; *P < 0.05 versus Caco-2 cells cultured with FBS; *P < 0.05 versus Caco-2 cells cultured with LTD₄.

The mitogenic effect observed with LTD₄ was confirmed using [³H]thymidine incorporation (Fig. 2). We found that LTD₄ (10 nmol/L) induced DNA synthesis, whereas the above mentioned CysLT₁R antagonists (i.e., MK 571 and LY 171883), the COX inhibitors, and the EP antagonists significantly inhibited the incorporation of [³H]thymidine into Caco-2 cells induced by LTD₄.

LTD₄ (10 nmol/L) was also able to induce a significant release of [³H]AA by Caco-2 cells, which was blocked in the presence of CystLT₁R antagonists (MK 571 and LY 171883) (Table 1). Moreover, the release of [³H]AA induced by LTD₄ was blocked by a number of inhibitors: a PLC inhibitor (U 73122); an inhibitor that prevents the release of calcium from the endoplasmic reticulum (dantrolene), and by a PKC inhibitor (Gö 6983). We observed that the release of [³H]AA induced by LTD₄ was also inhibited by a nonspecific phospholipase A₂ (PLA₂) inhibitor (AACOCF₃) but not by a specific calcium-independent PLA₂ inhibitor, for example, BEL. In addition, our study showed that LTD₄ (10 nmol/L) increases the expression of COX-2, and that this effect was reverted by a CysLT₁R antagonist (Fig. 3A). In addition, we found

Table 1. [3 H]AA release induced by leukotriene D₄ (LTD₄).

	[³ H]AA (%)
Control	4.1 ± 0.3
LTD ₄	23.6 ± 1.8*
LTD ₄ + AACOCF ₃ (10 μmol/L)	$8.2 \pm 0.7^{*,\#}$
$LTD_4 + BEL (10 \mu mol/L)$	21.3 ± 1.7*
LTD ₄ + MK 571 (25 μmol/L)	$7.2\pm1.1^{\#}$
LTD ₄ + LY 171883 (25 μmol/L)	$7.9\pm1.5^{\#}$
LTD ₄ + U 73122 (0.1 μmol/L)	11.5 ± 2.1*,*
LTD ₄ + Dantrolene (50 μmol/L)	12.6 ± 1.8*,#
LTD ₄ + Gö 6983 (1 μmol/L)	13.4 ± 1.3*,#

[³H]AA was determined in non-differentiated Caco-2 cell cultures, as described in the Materials and Methods section. Cells were incubated in the presence of LTD₄ (10 nmol/L) or LTD₄ plus treatments and [³H]AA was determined 30 min after LTD₄ incubation, respectively. Values are means \pm SEM of three experiments performed in triplicate, *P < 0.05 versus control; *P < 0.05 versus LTD₄.

that LTD₄ induced the synthesis of PGE₂ and that this action was reverted by CystLT₁R antagonists (MK 571 and LY 171883) and ketoprofen (Fig. 3B).

Finally, we studied the capacity of LTD₄ to phosphory-late pivotal elements in the cell signaling pathways implicated in the regulation of cell growth. For ERK, phosphorylation was highest after 5 min incubation and for CREB after 15 min. Dephosphorylation of β -catenin also increased after 15 min incubation (Fig. 4A). In addition, our results show that ERK phosphorylation induced by LTD₄ was reverted by a CysLT₁R antagonist as well as by a COX inhibitor (Fig. 4B) and that CREB phosphorylation induced by LTD₄ was also blocked by ketoprofen (Fig. 4B).

Discussion

Colorectal cancer is the third most common cancer in the Western world and almost half of patients die of metastatic disease. This highlights the importance of research into the molecular mechanisms involved and their role in prognosis. Previous findings in our laboratory have demonstrated that the release of AA by PLA2s participates in the signaling pathways involved in the control of intestinal epithelial cell proliferation (Sanchez and Moreno 2002a), and that its subsequent metabolism by COX-2 could be involved in the control of Caco-2 cell growth. Research has shown that in tumor tissue, COX and 5-LOX pathways are upregulated, which is not seen in normal colon mucosa (Cianchi et al. 2006). Moreover, as Cianchi et al. (2006) reported, 5-LOX inhibition increases the antitumor activity of COX inhibitors in human colon cancer cells. These findings support the hypothesis that




Figure 3. The effect of Leukotriene D_4 (LTD₄) on COX-2 expression and PGE₂ synthesis. (A) Cells were incubated in the absence of FBS (Control) and in the presence of LTD₄ (10 nmol/L) or LTD₄ plus LY171883 (LY1, 25 μmol/L) for 30 min and COX-2 expression was determined using a specific antibody. Murine COX-2 (20 ng) was used as standard (St COX-2). Western blot was used in three experiments. (B) Caco-2 cells were incubated with LTD₄ (1–100 nmol/L) for 15 min and PGE₂ synthesis was determined. PGE₂ synthesis induced by LTD₄ (10 nmol/L) was studied in the presence of MK 571 (MK5, 25 μmol/L), LY171883 (LY1, 25 μmol/L) or ketoprofen (Kp, 5 μmol/L). Results are expressed in mean \pm SEM of 5 determinations performed in triplicate. *P < 0.05 versus Caco-2 cell cultures in the absence of growth factors (FBS); $^{\#}P$ < 0.05 versus cells incubated with LTD₄ (10 nmol/L).

Figure 4. The effect of Leukotriene D₄ (LTD₄) on cell signaling. (A) Caco-2 cells were incubated with LTD₄ (10 nmol/L) for 5 or 15 min and then cells were collected. Phosphorylated Akt1, Akt2, ERK1/2, p38α, CREB, and GSKβ and dephosphorylated β-catenin were then measured, as described in the Material and Methods section. (B) The effect of LTD₄ (10 nmol/L) on ERK1/2 and CREB pathways. Cells were incubated with LTD₄ (10 nmol/L) for 5 min in the presence of LY171883 (LY1, 25 μmol/L) or ketoprofen (Kp, 5 μmol/L). Values are mean \pm SEM of triplicate determinations, the experiment was repeated twice. *P < 0.05 versus Caco-2 cells cultures in the absence of LTD₄ (10 nmol/L); * $^{\#}P$ < 0.05 versus cells incubated with LTD₄ (10 nmol/L).

the key elements of the AA cascade are involved in the regulation of intestinal epithelial structure/function (Ferrer and Moreno 2010).

Recently, we reported that pre-confluent Caco-2 cells were able to synthesize LTB₄ and 5-, and 12- and 15-

HETE eicosanoids, which were found to be involved in the regulation of Caco-2 cell growth (Cabral et al. 2013). Dreyling et al. (1986) reported that human gastrointestinal tissues could synthesize cysteinyl leukotrienes, however, we were unable to detect LTD₄ in Caco-2 cell culture supernatants (Cabral et al. 2013). Paruchuri et al. (2006) reported that cysteinyl LTs released from Caco-2

cells reached a concentration of 5 pmol/L, which is notably lower than the limits of detection (0.3 mmol/L) for this eicosanoid in our experimental conditions (Martín-Venegas et al. 2011).

It is important to consider that the tumor microenvironment has often been associated with infiltrating leukocytes in the tumor tissue and the surrounding stroma (Negus et al. 1997). Consequently, the activation of macrophages and mast cells in inflammatory processes and cancer might induce an additional release of cysteinyl LTs, such as LTD₄, in the intestinal mucosa. Thus, our findings demonstrate that at a concentration range of 1–100 nmol/L, which is a level likely reached under tumorigenic conditions, LTD₄ can induce Caco-2 cell proliferation and DNA synthesis. Moreover, our results have confirmed, using specific receptorial antagonists, that this effect is a consequence of the interaction with CystLT₁R.

This effect was also reported by Magnusson et al. (2007), who demonstrated that unlike CysLT₂R, CysLT₁R is involved in intestinal epithelial proliferation. Moreover, it has been described that this receptor is upregulated in colon cancer and correlates with a poorer prognosis (Ohd et al. 2003; Magnusson et al. 2010). Similarly, we recently reported that the LTD₄-CystLT₁R interaction increases intracellular Ca2+ concentrations in Caco-2 cells, indicating that PLC activation as well as stores of extracellular Ca2+ and intracellular Ca2+ are involved in this event (Rodríguez-Lagunas et al. 2013). Our results indicate that the PLC-IP₃-Ca²⁺/DAG-PKC signaling pathways and cytosolic PLA₂ participate in the release of [³H]AA induced by the LTD₄-CystLT₁R interaction. Consequently this also demonstrates their participation in the activation of the AA cascade and eicosanoid production. These findings are consistent with Parhamifar et al. (2005) who reported that cytosolic PLA2 was activated and translocated to the nucleus upon LTD₄ stimulation via a Ca²⁺dependent mechanism that involves the activation of PKC in Caco-2 cells.

Furthermore, we observed that the interaction of LTD₄ with the CystL₁T receptor stimulated COX-2 expression, which is consistent with previous research, carried out by Yudina et al. (2008) using different intestinal epithelial cells. We can therefore surmise that PGE₂ synthesis was induced by LTD₄, which is consistent with the results obtained by Öhd et al. (2000) and Massoumi et al. (2003). Given that Caco-2 cell proliferation induced by LTD₄ was reverted by nonspecific and specific COX inhibitors as well as EP₁ and EP₄ antagonists, we propose that this action is completely dependent of PGE₂ synthesized by both COX as well as by PGE₂ interaction with EP₁ and EP₄ that stimulated cell signaling pathways that are crucial in the progression of the cell cycle as previ-

ously described in our group (Cabral et al. 2013; Sanchez and Moreno 2002b). Thus, [³H]AA release, metabolism by both COXs, and the interaction of PGE₂ with EP₁ and EP₄ receptors are not only important events of acute and chronic inflammation, but are also essential regulators of the proliferation of transformed intestinal epithelial cancer cells induced by LTD₄.

We recently demonstrated the signaling pathways involved in Caco-2 cell growth induced by PGE2 to be ERK, CREB, GSK, and p38, which is consistent with Pham et al. (2008) and Cherukuri et al. (2007). Our results also indicate that LTD4 also induces ERK and CREB phosphorylation and that both signaling pathways were completely blocked when COX was inhibited. This therefore indicates that the activation of both ERK and CREB could be attributed to PGE₂ synthesis induced by LTD₄. Furthermore, while Caco-2 cells have a high basal β-catenin dephosphorylation level, we found that LTD₄ induces an additional dephosphorylation, which is consistent with research by Öhd et al. (2000). A previous study on Caco-2 cells in our laboratory revealed that this signaling pathway was not activated by a mitogenic factor such as PGE₂. Thus, since the mitogenic effect of LTD₄ is completely PGE2-dependent, it is unlikely that the activation of the β-catenin pathway by LTD₄ is directly related to cell proliferation, and so as reported by Salim et al. (2014), the dephosphorylation of β -catenin induced by LTD₄ could be linked to the migration of colon cancer

In conclusion, the effects of LTD₄ appear to occur through the increased expression and activation of COX-2, the production of PGE₂, and the interaction of PGE₂ with its cell-surface receptors. These findings will help improve our understanding of how inflammatory mediators can affect the survival and dissemination of intestinal carcinoma cells.

Acknowledgments

The authors thank Jaume Comas from the *Centres Cientí*fics i Tecnològics of the *Universitat de Barcelona* for his valuable help with apoptosis analyses. The Language Services of the *Universitat de Barcelona* are also gratefully acknowledged.

Conflict of Interest

No conflicts of interest, financial or otherwise, are declared by the authors.

References

Cabral, M., R. Martín-Venegas, and J. J. Moreno. 2013. Role of arachidonic acid metabolites on the control of non-

- differentiated intestinal epithelial cell growth. Int. J. Biochem. Cell Biol. 45:1620–1628.
- Cherukuri, D. P., X. B. O. Chen, A. C. Goulet, R. N. Young, Y. Han, R. L. Heimark, et al. 2007. The EP₄ receptor antagonist, L-161,982, blocks prostaglandin E₂-induced signal transduction and cell proliferation in HCA-7 colon cancer cells. Exp. Cell Res. 313:2969–2979.
- Cianchi, F., C. Cortesini, L. Magnelli, E. Fanti, L. Papucci, N. Schiavone, et al. 2006. Inhibition of 5-lipoxygenase by MK886 augments the antitumor activity of celecoxib in human colon cancer cells. Mol. Cancer Ther. 5:2716–2726.
- Coussens, L. M., and Z. Werb. 2002. Inflammation and cancer. Nature 420:860–867.
- Dreyling, K. W., U. Hoppe, B. A. Peskar, K. Morgenroth, W. Kozuschek, and B. M. Peskar. 1986. Leukotrienes synthesis by human gastrointestinal tissues. Biochim. Biophys. Acta 878:184–193.
- Ferrer, R., and J. J. Moreno. 2010. Role of eicosanoids on intestinal epithelial homeostasis. Biochem. Pharmacol. 80:431–438.
- Heise, C. E., B. F. O'Dowd, D. J. Figueroa, N. Sawyer, T. Nguyen, D. S. Im, et al. 2000. Characterization of the human cysteinyl leukotriene 2 receptor. J. Biol. Chem. 275:30531–30536.
- Lynch, K. R., G. P. O'Neill, Q. Liu, D. S. Im, N. Sawyer, and K. M. Metters. 1999. Characterization of the human cycteinyl leukotriene Cys LT1 receptor. Nature 399:789–793.
- Magnusson, C., R. Ehrnstrom, J. Olsen, and A. Sjolander. 2007. An increased expression of cysteinyl leukotriene 2 receptor in colorectal adenocarcinoma correlates with high differentiation. Cancer Res. 67:9190–9198.
- Magnusson, C., M. Mezhybovska, E. Lörinc, E. Fernebro, M. Nilbert, and A. Sjölander. 2010. Low expresión of CysLT1R and high expresión of CysLT2R mediate good prognosis in colorectal cancer. Eur. J. Cancer 46:826–835.
- Martín-Venegas, R., S. Roig-Pérez, R. Ferrer, and J. J. Moreno. 2006. Arachidonic acid cascade and epithelial barrier function during Caco-2 cell differentiation. J. Lipid Res. 47:1416–1423.
- Martín-Venegas, R., R. Casillas, O. Jauregui, and J. J. Moreno. 2011. Rapid simultaneous analysis of cyclooxygenase, lipoxygenase and cytochrome P-450 metabolites of arachidonic and linoleic acids using high performance liquid chromatography/mass spectrometry in tandem mode. J. Pharm. Biomed. Anal. 56:976–982.
- Massoumi, R., C. K. Nielsen, D. Azemovic, and A. Sjölander. 2003. Leukotriene D₄-induced adhesion of Caco-2 cells is mediated by prostaglandin E₂ and upregulation of alpha2beta1-integrin. Exp. Cell Res. 289:342–351.
- Negus, R. P., G. W. Stamp, J. Hadley, and F. R. Balkwill. 1997. Quantitative assessment of the leukocyte infiltrate in ovarian cancer and its relationship to the expression of C-C chemokines. Am. J. Pathol. 150:1723–1734.
- Öhd, J. F., K. Wikström, and A. Sjölander. 2000. Leukotrienes induce cell-survival signaling in intestinal epithelial cells. Gastroenterology 119:1007–1018.

- Öhd, J. F., C. K. Nielsen, J. Campbell, G. Landberg, H. Löfberg, and A. Sjölander. 2003. Expression of the leukotriene D₄ receptor CysLT1, COX-2, and other cell survival factors in colorectal adenocarcinomas. Gastroenterology 124:57–70.
- Parhamifar, L., B. Jeppsson, and A. Sjölander. 2005. Activation of cPLA₂ is required for leukotriene D4-induced proliferation in colon cancer cells. Carcinogenesis 26:1988–1998
- Parks, D. R., V. M. Bryan, V. T. Oi, and L. A. Herzenberg. 1979. Antigen-specific identification cloning of hybridomas with a fluorescence-activated cell sorter. Proc. Natl Acad. Sci. USA 76:1962–1969.
- Paruchuri, S., M. Mezhybovska, M. Juhas, and A. Sjölander. 2006. Endogenous production of leukotrienen D4 mediates autocrine survival and proliferation via CysLT1 receptor signaling in intestinal epithelial cells. Oncogene 25:6660–6665.
- Pham, H., G. Eibl, R. Vincenti, B. Chong, H. H. Tai, and L. W. Slice. 2008. 15-hydroxyprostaglandindehydrogenase suppresses K-Rasv12-dependent tumor formation in Nu/Numice. Mol. Carcinog. 47:466–477.
- Qiao, L., and X. Li. 2014. Role of chronic inflammation in cancers of the gastrointestinal system and the liver: where we are now. Cancer Lett. 345:150–152.
- Rodríguez-Lagunas, M. J., C. E. Storniolo, R. Ferrer, and J. J. Moreno. 2013. 5-Hydroxyeicosatetraenoic acid and leukotriene D₄ increase intestinal epithelial paracellular permeability. Int. J. Biochem. Cell Biol. 45:1318–1326.
- Salim, T., J. Sand-Dejmek, and A. Sjölander. 2014. The inflammatory mediator leukotriene D_4 induces subcellular β -catenin translocation and migration of colon cancer cells. Exp. Cell Res. 321:255–266.
- Samuelsson, B. 1979. Prostaglandins, thromboxanes and leukotrienes: formation and biological roles. Harvey Lect. 75:1–40.
- Sanchez, T., and J. J. Moreno. 2002a. Calcium-independent phospholipase A2 through arachidonic acid mobilization is involved in Caco-2 cell growth. J. Cell. Physiol. 193:293–298.
- Sanchez, T., and J. J. Moreno. 2002b. Role of EP₁ and EP₄ PGE₂ subtype receptors in serum-induced 3T6 fibrobalst cycle progression and proliferation. Am. J. Physiol. Cell Physiol. 282:C280–C288.
- Smalley, W. E., and R. Dubois. 1997. Colorectal cancer and nonsteroidal anti-inflammatory drugs. Adv. Pharmacol. 39:1–20.
- Stenton, W. F. 1990. Role of eicosanoids as mediators of inflammation in inflammatory bowel disease. Scand. J. Gastroenterol. 172:13–18.
- Yudina, Y., L. Parhamifar, A. M. L. Bengtsson, M. Juhas, and A. Sjölander. 2008. Regulation of the eicosanoid pathway by tumour necrosis factor alpha and leukotriene D₄ in intestinal epithelial cells. Prostaglandins Leukot. Essent. Fatty Acids 79:223–231.